<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130304012695N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-03</date_registration>
      <primary_sponsor>Deputy of Research,Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of diphenhydramine propofol with ketamine propofol on analgesia in male patients under  cystoscopy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison effect of Diphenhydramine-propofol versus ketamine-propofol in improving the quality of deep sedation in male patients undergoing rigid cystoscopy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63295</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize patients with inclusion criteria Block balanced randomization is used.Before studying, one of the person who is not a member of the research team performs the randomization process by using Random generator software, forms four blocks for the intervention and control group. The complete cards of the four blocks are given to the head of the operating room, who is unaware of the study, in an envelope. A card is given to the patient after patient entrance to operating room, Blinding description: To randomize patients with inclusion criteria Block balanced randomization is used.Before studying, one of the person who is not a member of the research team performs the randomization process by using Random generator software, forms four blocks for the intervention and control group. The complete cards of the four blocks are given to the head of the operating room, who is unaware of the study, in an envelope. A card is given to the patient after patient entrance to operating room.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Cystoscopy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First, midazolam was injected 0.03 mg / kg, fentanyl  2µ /kg intravenously, then patients in the Diphenhydramine group received 0.6 mg / kg diphenhydramine intravenously. Propofol 0.5 mg / kg is injected 3 minutes after injection of these drugs and 60 seconds before the start of cystoscopy. Then the quality of sedation, pain and hemodynamic changes are examined during cystoscopy. In case of pain and movements that indicate the patient's intolerance, propofol is injected again to calm the patient. Intervention 2: Control group: First, midazolam was injected 0.03 mg / kg, fentanyl  2µ /kg intravenously, then patients in the Ketamine group received 0.6 mg / kg ketamine intravenously. Propofol 0.5 mg / kg is injected 3 minutes after injection of these drugs and 60 seconds before the start of cystoscopy. Then the quality of sedation, pain and hemodynamic changes are examined during cystoscopy. In case of pain and movements that indicate the patient's intolerance, propofol is injected again to calm the patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Main study outcome data

When:
Six months after the end of the study

To whom:
University  researchers

Conditions:
Share experiences to increase the knowledge

Where to obtain:
khajavim@tums.ac.ir 
Dr.khajavi

How to obtain:
Through Dr. Khajavi
 e-mail address: khajavim@tums.ac.ir

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam khomeni St, Hasan Abad Sq, Sina hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 0000</telephone>
        <email>khajavim@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam khomeni St, Hasan Abad Sq, Sina hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 0000</telephone>
        <email>khajavim@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>male patient Age 20 to 75 years old Cystoscopy candidate
ASA Class 1 and 2
No allergy to used drugs
No history of cardio-pulmonary-liver and kidney disease
Lack of Obstructive Sleep Apnea (OSA)
No history of drug addiction or other psychotropic substances
No history of acute drug or alcohol poisoning
No history of psychological illness</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>75 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of closed glaucoma
History of dry mouth disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First, midazolam was injected 0.03 mg / kg, fentanyl  2µ /kg intravenously, then patients in the Diphenhydramine group received 0.6 mg / kg diphenhydramine intravenously. Propofol 0.5 mg / kg is injected 3 minutes after injection of these drugs and 60 seconds before the start of cystoscopy. Then the quality of sedation, pain and hemodynamic changes are examined during cystoscopy. In case of pain and movements that indicate the patient's intolerance, propofol is injected again to calm the patient.</i_keyword>
      <i_keyword>Control group: First, midazolam was injected 0.03 mg / kg, fentanyl  2µ /kg intravenously, then patients in the Ketamine group received 0.6 mg / kg ketamine intravenously. Propofol 0.5 mg / kg is injected 3 minutes after injection of these drugs and 60 seconds before the start of cystoscopy. Then the quality of sedation, pain and hemodynamic changes are examined during cystoscopy. In case of pain and movements that indicate the patient's intolerance, propofol is injected again to calm the patient.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Duration of Cystoscopy. Timepoint: Once .Start and end of Cystoscopy. Method of measurement: With stopwatch.</prim_outcome>
      <prim_outcome>Mean Arterial Blood Pressure. Timepoint: Before the cystoscope enters the urethra and bladder, 30 seconds after entering the urethra, then every 2 minutes. Method of measurement: Non-invasive and automatically.</prim_outcome>
      <prim_outcome>Heart Rate. Timepoint: Before the cystoscope enters the urethra and bladder, 30 seconds after entering the urethra, then every 2 minutes. Method of measurement: from monitor.</prim_outcome>
      <prim_outcome>The amount of propofol consumed. Timepoint: Once at the end of cystoscopy. Method of measurement: In milligrams.</prim_outcome>
      <prim_outcome>Patient response when a cystoscope enters the urethra. Timepoint: When the cystoscope enters the urethra. Method of measurement: Observe the patient's movements and rate it from 0-3 according to the type of movements.</prim_outcome>
      <prim_outcome>Pain intensity. Timepoint: During cystoscopy and in recovery. Method of measurement: visual analog scale (VAS).</prim_outcome>
      <prim_outcome>Quality and satisfaction of the surgeon from Sedition. Timepoint: At the end of cystoscopy. Method of measurement: Ask the surgeon and score from 1-4.</prim_outcome>
      <prim_outcome>Quality and patient satisfaction from sedation. Timepoint: in recovery room. Method of measurement: Ask the patients and score from 1-4.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of Research,Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-02</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Sina hospital; Hasan Abad square; Emam khomeni street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
